Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Ann Thorac Surg. 2018 May;105(5):1483-1491. doi: 10.1016/j.athoracsur.2018.01.032. Epub 2018 Feb 17.
This study aimed to compare the survival rates after lobectomy, segmentectomy, and wedge resection for the eighth edition of the tumor, node, metastasis classification for stage IA non-small cell lung cancer (NSCLC).
Patients who underwent lobectomy, segmentectomy, or wedge resection for stage IA NSCLC were identified from the Surveillance, Epidemiology, and End Results database. A Cox regression model and propensity-matched analysis were used. The overall survival (OS) rates and lung cancer-specific survival (LCSS) rates among the three groups were compared by tumor size.
A total of 16,819 patients met our criteria. Although the OS rate was better for lobectomy than for wedge resection, no statistical differences in the LCSS rate were identified among the three treatment groups of patients with tumors that were 1.0 cm or smaller. For tumors from 1.1 to 2.0 cm, lobectomy and segmentectomy showed no statistical differences in the LCSS rate, but both conferred better OS and LCSS rates than wedge resection. For tumors from 2.1 to 3.0 cm, the OS and LCSS rates were better for lobectomy than for segmentectomy or wedge resection, but similar for segmentectomy and wedge resection.
Lobectomy, segmentectomy, and wedge resection are comparable oncologic procedures for patients with stage IA NSCLC that is 1.0 cm or smaller. For tumors from 1.1 to 2.0 cm, lobectomy and segmentectomy could lead to equivalent survival rates but showed better survival rates than that observed with wedge resection. For tumors from 2.1 to 3.0 cm, lobectomy is still the standard surgical procedure; for patients who are unsuitable candidates for lobectomy, segmentectomy and wedge resection show similar survival rates.
本研究旨在比较第八版肿瘤、淋巴结、转移分期的 IA 期非小细胞肺癌(NSCLC)行肺叶切除术、节段切除术和楔形切除术的生存率。
从监测、流行病学和最终结果数据库中确定了接受 IA 期 NSCLC 肺叶切除术、节段切除术或楔形切除术的患者。使用 Cox 回归模型和倾向匹配分析。通过肿瘤大小比较三组患者的总生存率(OS)和肺癌特异性生存率(LCSS)。
共有 16819 名患者符合我们的标准。虽然肺叶切除术的 OS 率优于楔形切除术,但在肿瘤大小为 1.0cm 或更小的三组患者中,LCSS 率无统计学差异。对于 1.1 至 2.0cm 的肿瘤,肺叶切除术和节段切除术的 LCSS 率无统计学差异,但均优于楔形切除术的 OS 和 LCSS 率。对于 2.1 至 3.0cm 的肿瘤,肺叶切除术的 OS 和 LCSS 率优于节段切除术或楔形切除术,但节段切除术和楔形切除术相似。
对于肿瘤大小为 1.0cm 或更小的 IA 期 NSCLC 患者,肺叶切除术、节段切除术和楔形切除术是可比较的肿瘤学治疗方法。对于 1.1 至 2.0cm 的肿瘤,肺叶切除术和节段切除术可导致等效的生存率,但优于楔形切除术的生存率。对于 2.1 至 3.0cm 的肿瘤,肺叶切除术仍然是标准的手术程序;对于不适合肺叶切除术的患者,节段切除术和楔形切除术显示出相似的生存率。